{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:04:56Z","timestamp":1780027496595,"version":"3.53.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10640-4","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:29:44Z","timestamp":1780018184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["State-of-the-art management of ischemic cardiomyopathy: integrating diagnostic pathways, revascularization strategies, and guideline-directed therapy"],"prefix":"10.1007","volume":"31","author":[{"given":"Matteo","family":"Busti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojtech","family":"Melenovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Colli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Monzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"9","key":"10640_CR1","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","volume":"93","author":"A Mosterd","year":"2007","unstructured":"Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93(9):1137\u20131146","journal-title":"Heart"},{"issue":"1","key":"10640_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMra1112570","volume":"366","author":"EG Nabel","year":"2012","unstructured":"Nabel EG, Braunwald E (2012) A tale of coronary artery disease and myocardial infarction. N Engl J Med 366(1):54\u201363","journal-title":"N Engl J Med"},{"key":"10640_CR3","doi-asserted-by":"publisher","first-page":"133251","DOI":"10.1016\/j.ijcard.2025.133251","volume":"431","author":"L Monzo","year":"2025","unstructured":"Monzo L, Girerd N (2025) EMPACT-ing prognosis: Tailoring SGLT2i therapy with GDF-15. Int J Cardiol 431:133251","journal-title":"Int J Cardiol"},{"issue":"1","key":"10640_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ehf2.13070","volume":"8","author":"D Kamon","year":"2021","unstructured":"Kamon D, Sugawara Y, Soeda T, Okamura A, Nakada Y, Hashimoto Y et al (2021) Predominant subtype of heart failure after acute myocardial infarction is heart failure with non-reduced ejection fraction. ESC Heart Fail 8(1):317\u2013325","journal-title":"ESC Heart Fail"},{"issue":"10","key":"10640_CR5","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/ejhf.2986","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Huttin O, Ferreira JP, Lamiral Z, Bozec E, Beaumont M et al (2023) Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: The REMI study. Eur J Heart Fail 25(10):1742\u20131752","journal-title":"Eur J Heart Fail"},{"key":"10640_CR6","doi-asserted-by":"publisher","unstructured":"Al-Awar A, Khan AW, Hussain S (2025) Myocardial stunning: mechanisms, molecular insights, and gaps in knowledge. Biosci Rep. 2025 Dec 16;45(12):BSR20253410 https:\/\/doi.org\/10.1042\/BSR20253410","DOI":"10.1042\/BSR20253410"},{"issue":"1","key":"10640_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","volume":"4","author":"MA Konstam","year":"2011","unstructured":"Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE (2011) Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 4(1):98\u2013108","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9932","key":"10640_CR8","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/S0140-6736(14)60107-0","volume":"383","author":"G Heusch","year":"2014","unstructured":"Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G et al (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383(9932):1933\u20131943","journal-title":"Lancet"},{"issue":"2","key":"10640_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0735-1097(01)01738-7","volume":"39","author":"GM Felker","year":"2002","unstructured":"Felker GM, Shaw LK, O\u2019Connor CM (2002) A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 39(2):210\u2013218","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10640_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ejhf.1747","volume":"22","author":"I Cabac-Pogorevici","year":"2020","unstructured":"Cabac-Pogorevici I, Muk B, Rustamova Y, Kalogeropoulos A, Tzeis S, Vardas P (2020) Ischaemic cardiomyopathy. Pathophysiological insights, diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology. Eur J Heart Fail 22(5):789\u2013799","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"10640_CR11","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1161\/CIRCULATIONAHA.120.049755","volume":"144","author":"HR Reynolds","year":"2021","unstructured":"Reynolds HR, Shaw LJ, Min JK, Page CB, Berman DS, Chaitman BR et al (2021) Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. Circulation 144(13):1024\u20131038","journal-title":"Circulation"},{"issue":"10","key":"10640_CR12","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1001\/jamainternmed.2014.164","volume":"174","author":"GA Lin","year":"2014","unstructured":"Lin GA, Dudley RA (2014) Fighting the oculostenotic reflex. JAMA Intern Med 174(10):1621\u20131622","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10640_CR13","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.4244\/EIJV12I2A36","volume":"12","author":"J Escaned","year":"2016","unstructured":"Escaned J, Banning A, Farooq V, Echavarria-Pinto M, Onuma Y, Ryan N et al (2016) Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease. EuroIntervention 12(2):e224\u2013e234","journal-title":"EuroIntervention"},{"issue":"2","key":"10640_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.amjcard.2012.09.012","volume":"111","author":"K De Silva","year":"2013","unstructured":"De Silva K, Morton G, Sicard P, Chong E, Indermuehle A, Clapp B et al (2013) Prognostic utility of BCIS myocardial jeopardy score for classification of coronary disease burden and completeness of revascularization. Am J Cardiol 111(2):172\u2013177","journal-title":"Am J Cardiol"},{"issue":"8","key":"10640_CR15","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1093\/ehjci\/jeab053","volume":"22","author":"AG Almeida","year":"2021","unstructured":"Almeida AG, Carpenter JP, Cameli M, Donal E, Dweck MR, Flachskampf FA et al (2021) Multimodality imaging of myocardial viability: an expert consensus document from the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging 22(8):e97\u2013e125","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"7","key":"10640_CR16","doi-asserted-by":"publisher","first-page":"e000053","DOI":"10.1161\/HCI.0000000000000053","volume":"13","author":"MJ Garcia","year":"2020","unstructured":"Garcia MJ, Kwong RY, Scherrer-Crosbie M, Taub CC, Blankstein R, Lima J et al (2020) State of the Art: Imaging for Myocardial Viability: A Scientific Statement From the American Heart Association. Circ Cardiovasc Imaging 13(7):e000053","journal-title":"Circ Cardiovasc Imaging"},{"issue":"12","key":"10640_CR17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1161\/CIRCULATIONAHA.110.011346","volume":"124","author":"RG Assomull","year":"2011","unstructured":"Assomull RG, Shakespeare C, Kalra PR, Lloyd G, Gulati A, Strange J et al (2011) Role of cardiovascular magnetic resonance as a gatekeeper to invasive coronary angiography in patients presenting with heart failure of unknown etiology. Circulation 124(12):1351\u20131360","journal-title":"Circulation"},{"issue":"4","key":"10640_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11886-023-01851-4","volume":"25","author":"L Alam","year":"2023","unstructured":"Alam L, Omar AMS, Patel KK (2023) Improved Performance of PET Myocardial Perfusion Imaging Compared to SPECT in the Evaluation of Suspected CAD. Curr Cardiol Rep 25(4):281\u2013293","journal-title":"Curr Cardiol Rep"},{"issue":"7","key":"10640_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cpcardiol.2007.04.001","volume":"32","author":"AF Schinkel","year":"2007","unstructured":"Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH (2007) Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 32(7):375\u2013410","journal-title":"Curr Probl Cardiol"},{"issue":"6","key":"10640_CR20","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1007\/s00330-024-11283-5","volume":"35","author":"M Gatti","year":"2025","unstructured":"Gatti M, De Filippo O, Cura Cura G, Dusi V, Di Vita U, Gallone G et al (2025) Diagnostic accuracy of late iodine enhancement on cardiac CT for myocardial tissue characterization: a systematic review and meta-analysis. Eur Radiol 35(6):3054\u20133067","journal-title":"Eur Radiol"},{"issue":"2","key":"10640_CR21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jcmg.2025.08.016","volume":"19","author":"RA Kotronias","year":"2026","unstructured":"Kotronias RA, Portolan L, Xie C, Ferreira VM, Raman B, Klotz E et al (2026) Evaluating Acute Ischemic Myocardial Injury With Photon-Counting Computed Tomography. JACC Cardiovasc Imaging 19(2):284\u2013287","journal-title":"JACC Cardiovasc Imaging"},{"issue":"36","key":"10640_CR22","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J et al (2024) 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 45(36):3415\u20133537","journal-title":"Eur Heart J"},{"issue":"9","key":"10640_CR23","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH et al (2023) 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 148(9):e9\u2013e119","journal-title":"Circulation"},{"issue":"8","key":"10640_CR24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa1807365","volume":"381","author":"JA Panza","year":"2019","unstructured":"Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK et al (2019) Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. N Engl J Med 381(8):739\u2013748","journal-title":"N Engl J Med"},{"issue":"20","key":"10640_CR25","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.jacc.2007.09.006","volume":"50","author":"RS Beanlands","year":"2007","unstructured":"Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M et al (2007) F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 50(20):2002\u20132012","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10640_CR26","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.jcmg.2020.05.034","volume":"13","author":"Y Ge","year":"2020","unstructured":"Ge Y, Antiochos P, Steel K, Bingham S, Abdullah S, Chen YY et al (2020) Prognostic Value of Stress CMR Perfusion Imaging in Patients With Reduced Left Ventricular Function. JACC Cardiovasc Imaging 13(10):2132\u20132145","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"10640_CR27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1001\/jama.2013.1381","volume":"309","author":"DJ Shah","year":"2013","unstructured":"Shah DJ, Kim HW, James O, Parker M, Wu E, Bonow RO et al (2013) Prevalence of regional myocardial thinning and relationship with myocardial scarring in patients with coronary artery disease. JAMA 309(9):909\u2013918","journal-title":"JAMA"},{"issue":"12","key":"10640_CR28","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jacc.2014.06.1194","volume":"64","author":"I Eitel","year":"2014","unstructured":"Eitel I, de Waha S, Wohrle J, Fuernau G, Lurz P, Pauschinger M et al (2014) Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol 64(12):1217\u20131226","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10640_CR29","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"issue":"1","key":"10640_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M et al (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 24(1):4\u2013131","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10640_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr., Cuddy TE et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327(10):669\u2013677","journal-title":"N Engl J Med"},{"issue":"22","key":"10640_CR32","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1161\/CIRCULATIONAHA.105.551143","volume":"112","author":"HD White","year":"2005","unstructured":"White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S et al (2005) Mortality and morbidity remain high despite captopril and\/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 112(22):3391\u20133399","journal-title":"Circulation"},{"issue":"9","key":"10640_CR33","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"JJ McMurray","year":"2013","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15(9):1062\u20131073","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"10640_CR34","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","volume":"385","author":"MA Pfeffer","year":"2021","unstructured":"Pfeffer MA, Claggett B, Lewis EF, Granger CB, Kober L, Maggioni AP et al (2021) Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med 385(20):1845\u20131855","journal-title":"N Engl J Med"},{"issue":"9146","key":"10640_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","unstructured":"CIBIS-II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353(9146):9\u201313","journal-title":"Lancet"},{"issue":"9169","key":"10640_CR36","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"Effect of metoprolol CR\/XL in chronic heart failure","year":"1999","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure (1999) Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169):2001\u20132007","journal-title":"Lancet"},{"issue":"9266","key":"10640_CR37","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"HJ Dargie","year":"2001","unstructured":"Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357(9266):1385\u20131390","journal-title":"Lancet"},{"issue":"17","key":"10640_CR38","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H et al (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106(17):2194\u20132199","journal-title":"Circulation"},{"issue":"3","key":"10640_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26(3):215\u2013225","journal-title":"Eur Heart J"},{"key":"10640_CR40","doi-asserted-by":"crossref","unstructured":"Castiello DS, Calvelli P, Anniballo A, Romano LR, Polimeni A, Curcio A (2026) The prognostic impact of beta blockers in ischemic heart failure: time for a paradigm shift? Heart Fail Rev 31, 41","DOI":"10.1007\/s10741-026-10615-5"},{"issue":"16","key":"10640_CR41","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","volume":"118","author":"B Pitt","year":"2008","unstructured":"Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, Investigators E (2008) Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118(16):1643\u20131650","journal-title":"Circulation"},{"issue":"1","key":"10640_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"8","key":"10640_CR43","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/ejhf.2952","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Girerd N, Duarte K, Ferreira JP, McMurray JJV, van Veldhuisen DJ et al (2023) Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial. Eur J Heart Fail 25(8):1444\u20131449","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10640_CR44","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709\u2013717","journal-title":"N Engl J Med"},{"issue":"Suppl C","key":"10640_CR45","doi-asserted-by":"publisher","first-page":"C309","DOI":"10.1093\/eurheartjsupp\/suad055","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Ferrari I, Cicogna F, Tota C, Cice G, Girerd N et al (2023) Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians. Eur Heart J Suppl 25(Suppl C):C309\u2013C15","journal-title":"Eur Heart J Suppl"},{"issue":"21","key":"10640_CR46","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"issue":"15","key":"10640_CR47","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"issue":"6","key":"10640_CR48","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1002\/ehf2.15420","volume":"12","author":"D Erlinge","year":"2025","unstructured":"Erlinge D, James S, Deanfield J, Eriksson N, de Belder M, Alchay M et al (2025) Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. ESC Heart Fail 12(6):4184\u20134193","journal-title":"ESC Heart Fail"},{"issue":"16","key":"10640_CR49","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J et al (2024) Empagliflozin after Acute Myocardial Infarction. N Engl J Med 390(16):1455\u20131466","journal-title":"N Engl J Med"},{"issue":"10510","key":"10640_CR50","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","volume":"406","author":"J Butler","year":"2025","unstructured":"Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M et al (2025) Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 406(10510):1341\u20131350","journal-title":"Lancet"},{"issue":"1","key":"10640_CR51","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10741-025-10593-0","volume":"31","author":"O Geavlete","year":"2026","unstructured":"Geavlete O, Ambrosy AP, Skowronski J, Abdelhamid M, Girerd N, Alexy T et al (2026) The DIGIT-HF trial and the Mihai Gheorghiade legacy: time to reconsider cardiac glycosides as effective therapy in HFrEF. Heart Fail Rev 31(1):18","journal-title":"Heart Fail Rev"},{"issue":"9744","key":"10640_CR52","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875\u2013885","journal-title":"Lancet"},{"issue":"12","key":"10640_CR53","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1002\/ejhf.70047","volume":"27","author":"M Kobayashi","year":"2025","unstructured":"Kobayashi M, Duarte K, Ferreira JP, Baudry G, Monzo L, McMurray JJV et al (2025) An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 27(12):2800\u20132809","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10640_CR54","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1002\/ejhf.70076","volume":"27","author":"E Bresso","year":"2025","unstructured":"Bresso E, Lacomblez C, Duarte K, Monzo L, Baudry G, Tromp J et al (2025) Unsupervised machine learning for cardiovascular disease: A framework for future studies. Eur J Heart Fail 27(12):3366\u20133377","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10640_CR55","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1002\/ejhf.3547","volume":"27","author":"L Monzo","year":"2025","unstructured":"Monzo L, Bresso E, Dickstein K, Pitt B, Cleland JGF, Anker SD et al (2025) Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction. Eur J Heart Fail 27(12):3378\u20133391","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10640_CR56","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","volume":"357","author":"J Kjekshus","year":"2007","unstructured":"Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH et al (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357(22):2248\u20132261","journal-title":"N Engl J Med"},{"issue":"6","key":"10640_CR57","doi-asserted-by":"publisher","first-page":"e026943","DOI":"10.1161\/JAHA.122.026943","volume":"12","author":"R Liga","year":"2023","unstructured":"Liga R, Colli A, Taggart DP, Boden WE, De Caterina R (2023) Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: For Whom and How. J Am Heart Assoc 12(6):e026943","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10640_CR58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/eurjhf\/hfq230","volume":"13","author":"JG Cleland","year":"2011","unstructured":"Cleland JG, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS et al (2011) The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail 13(2):227\u2013233","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10640_CR59","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","volume":"364","author":"EJ Velazquez","year":"2011","unstructured":"Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A et al (2011) Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 364(17):1607\u20131616","journal-title":"N Engl J Med"},{"issue":"16","key":"10640_CR60","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","volume":"374","author":"EJ Velazquez","year":"2016","unstructured":"Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA et al (2016) Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med 374(16):1511\u20131520","journal-title":"N Engl J Med"},{"issue":"15","key":"10640_CR61","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","volume":"387","author":"D Perera","year":"2022","unstructured":"Perera D, Clayton T, O\u2019Kane PD, Greenwood JP, Weerackody R, Ryan M et al (2022) Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med 387(15):1351\u20131360","journal-title":"N Engl J Med"},{"issue":"1","key":"10640_CR62","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/01.CIR.89.1.151","volume":"89","author":"CA Beltrami","year":"1994","unstructured":"Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E et al (1994) Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89(1):151\u2013163","journal-title":"Circulation"},{"issue":"2","key":"10640_CR63","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/eurheartj\/ehab729","volume":"43","author":"M Ryan","year":"2022","unstructured":"Ryan M, Morgan H, Chiribiri A, Nagel E, Cleland J, Perera D (2022) Myocardial viability testing: all STICHed up, or about to be REVIVED? Eur Heart J 43(2):118\u2013126","journal-title":"Eur Heart J"},{"issue":"18","key":"10640_CR64","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.120.050304","volume":"142","author":"RD Lopes","year":"2020","unstructured":"Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Pina IL et al (2020) Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial. Circulation 142(18):1725\u20131735","journal-title":"Circulation"},{"issue":"5","key":"10640_CR65","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/ejcts\/ezac068","volume":"61","author":"A De Martino","year":"2022","unstructured":"De Martino A, Del Re F, Gregori D, Azzolina D, Pascarella C, Falcetta G et al (2022) Surgical revascularization for stable coronary syndrome: the ISCHEMIA trial versus a single-centre matched population-a real-world analysis of patients undergoing surgical revascularization. Eur J Cardiothorac Surg 61(5):1155\u20131161","journal-title":"Eur J Cardiothorac Surg"},{"issue":"8","key":"10640_CR66","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jacc.2017.12.024","volume":"71","author":"J Nagendran","year":"2018","unstructured":"Nagendran J, Bozso SJ, Norris CM, McAlister FA, Appoo JJ, Moon MC et al (2018) Coronary Artery Bypass Surgery Improves Outcomes in Patients With Diabetes and Left Ventricular Dysfunction. J Am Coll Cardiol 71(8):819\u2013827","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10640_CR67","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.jacc.2020.07.047","volume":"76","author":"S Park","year":"2020","unstructured":"Park S, Ahn JM, Kim TO, Park H, Kang DY, Lee PH et al (2020) Revascularization in Patients With Left Main Coronary Artery Disease and Left Ventricular Dysfunction. J Am Coll Cardiol 76(12):1395\u20131406","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10640_CR68","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.amjcard.2014.07.007","volume":"114","author":"A Marui","year":"2014","unstructured":"Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M et al (2014) Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions\u2009\u2264\u200950% versus >\u200950% (from the CREDO-Kyoto PCI\/CABG Registry Cohort-2). Am J Cardiol 114(7):988\u2013996","journal-title":"Am J Cardiol"},{"issue":"2","key":"10640_CR69","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.hfc.2024.12.009","volume":"21","author":"Y Kamani","year":"2025","unstructured":"Kamani Y, Peigh G, Verma N, Wasserlauf J (2025) Cardiac Implantable Electronic Devices in Ischemic Cardiomyopathy. Heart Fail Clin 21(2):309\u2013326","journal-title":"Heart Fail Clin"},{"issue":"1","key":"10640_CR70","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.hrthm.2024.05.057","volume":"22","author":"L Gerra","year":"2025","unstructured":"Gerra L, Bonini N, Mei DA, Imberti JF, Vitolo M, Bucci T et al (2025) Cardiac resynchronization therapy (CRT) nonresponders in the contemporary era: A state-of-the-art review. Heart Rhythm 22(1):159\u2013169","journal-title":"Heart Rhythm"},{"issue":"26","key":"10640_CR71","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","volume":"335","author":"AJ Moss","year":"1996","unstructured":"Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H et al (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335(26):1933\u20131940","journal-title":"N Engl J Med"},{"issue":"12","key":"10640_CR72","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","volume":"346","author":"AJ Moss","year":"2002","unstructured":"Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346(12):877\u2013883","journal-title":"N Engl J Med"},{"issue":"3","key":"10640_CR73","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352(3):225\u2013237","journal-title":"N Engl J Med"},{"issue":"1","key":"10640_CR74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609758","volume":"377","author":"L Shen","year":"2017","unstructured":"Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF et al (2017) Declining Risk of Sudden Death in Heart Failure. N Engl J Med 377(1):41\u201351","journal-title":"N Engl J Med"},{"issue":"5","key":"10640_CR75","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1536\/ihj.24-023","volume":"65","author":"G Yuecel","year":"2024","unstructured":"Yuecel G, Gaasch L, Hetjens S, Oeztuerk ON, Yildirim G, Pfleger S et al (2024) Cardiac Resynchronization Therapy with Defibrillator in Ischemic Versus Nonischemic Cardiomyopathy. Int Heart J 65(5):823\u2013832","journal-title":"Int Heart J"},{"key":"10640_CR76","doi-asserted-by":"crossref","unstructured":"Gorenek B, Wijnmaalen AP, Goette A, Mert GO, Porter B, Gustafsson F et al (2024) Ventricular arrhythmias in acute heart failure: a clinical consensus statement of the Association for Acute CardioVascular Care, the European Heart Rhythm Association, and the Heart Failure Association of the European Society of Cardiology. Europace. 2024 Oct 3;26(10):euae235.","DOI":"10.1093\/europace\/euae235"},{"issue":"2","key":"10640_CR77","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1513614","volume":"375","author":"JL Sapp","year":"2016","unstructured":"Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF et al (2016) Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med 375(2):111\u2013121","journal-title":"N Engl J Med"},{"issue":"8","key":"10640_CR78","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa2409501","volume":"392","author":"JL Sapp","year":"2025","unstructured":"Sapp JL, Tang ASL, Parkash R, Stevenson WG, Healey JS, Gula LJ et al (2025) Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia. N Engl J Med 392(8):737\u2013747","journal-title":"N Engl J Med"},{"issue":"25","key":"10640_CR79","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.122.059598","volume":"145","author":"P Della Bella","year":"2022","unstructured":"Della Bella P, Baratto F, Vergara P, Bertocchi P, Santamaria M, Notarstefano P et al (2022) Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial. Circulation 145(25):1829\u20131838","journal-title":"Circulation"},{"issue":"24","key":"10640_CR80","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM et al (2018) Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 379(24):2307\u20132318","journal-title":"N Engl J Med"},{"issue":"19","key":"10640_CR81","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa2314328","volume":"391","author":"SD Anker","year":"2024","unstructured":"Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M et al (2024) Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation. N Engl J Med 391(19):1799\u20131809","journal-title":"N Engl J Med"},{"issue":"24","key":"10640_CR82","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","volume":"379","author":"JF Obadia","year":"2018","unstructured":"Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N et al (2018) Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med 379(24):2297\u20132306","journal-title":"N Engl J Med"},{"issue":"24","key":"10640_CR83","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.jacc.2024.08.026","volume":"84","author":"MS Anker","year":"2024","unstructured":"Anker MS, Porthun J, Bonnet G, Schulze PC, Rassaf T, Landmesser U (2024) Percutaneous Transcatheter Edge-to-Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Meta-Analysis of 3 Randomized Controlled Trials. J Am Coll Cardiol 84(24):2364\u20132368","journal-title":"J Am Coll Cardiol"},{"issue":"44","key":"10640_CR84","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1093\/eurheartj\/ehaf194","volume":"46","author":"F Praz","year":"2025","unstructured":"Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M et al (2025) 2025 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 46(44):4635\u20134736","journal-title":"Eur Heart J"},{"issue":"8","key":"10640_CR85","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/ejhf.1922","volume":"22","author":"O Chioncel","year":"2020","unstructured":"Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J et al (2020) Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 22(8):1315\u20131341","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10640_CR86","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJMoa1900486","volume":"380","author":"MR Mehra","year":"2019","unstructured":"Mehra MR, Uriel N, Naka Y, Cleveland JC Jr., Yuzefpolskaya M, Salerno CT et al (2019) A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. N Engl J Med 380(17):1618\u20131627","journal-title":"N Engl J Med"},{"issue":"1","key":"10640_CR87","doi-asserted-by":"publisher","first-page":"E39","DOI":"10.1503\/cjs.005719","volume":"64","author":"C Wavell","year":"2021","unstructured":"Wavell C, Sokolowski A, Klingel ML, Yin C, Nagpal AD (2021) Clinical effectiveness of therapy with continuous-flow left ventricular assist devices in nonischemic versus ischemic cardiomyopathy: a systematic review and meta-analysis. Can J Surg 64(1):E39\u2013E47","journal-title":"Can J Surg"},{"key":"10640_CR88","doi-asserted-by":"crossref","unstructured":"Uriel N, Sayer GT, Elad B, Fried JA, Raikhelkar JK, Lotan D et al (2026) Heart replacement therapy in young patients: a comparative analysis of HeartMate 3 LVAD and heart transplant using MOMENTUM 3 and UNOS Registry. JACC Heart Fail. 2026 Apr;14(4):102948","DOI":"10.1016\/j.jchf.2026.102948"},{"issue":"25 Pt A","key":"10640_CR89","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.jacc.2014.03.034","volume":"63","author":"SJ Hwang","year":"2014","unstructured":"Hwang SJ, Melenovsky V, Borlaug BA (2014) Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 63(25 Pt A):2817\u20132827","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10640_CR90","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jamacardio.2021.1825","volume":"6","author":"CJ Rush","year":"2021","unstructured":"Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM et al (2021) Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol 6(10):1130\u20131143","journal-title":"JAMA Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10640-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10640-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10640-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T03:56:01Z","timestamp":1780026961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10640-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10640"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10640-4","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"V. M. serves as consultant for Bayer, Novo Nordisk, Boehringer-Ingelheim, Abbott and receives grant support from Regeneron. G.S. reports grants and personal fees from CSL Vifor, Boehringer Ingelheim, AstraZeneca, Servier, Novartis, Cytokinetics, Pharmacosmos, Medtronic, Bayer, and personal fees from Roche, Abbott, Edwards Lifescience, TEVA, Menarini, INTAS, GETZ, Hikma, Laboratori Guidotti, and grants from Boston Scientific, Merck. O.C. reports speaker fee from ELLY LILY and grant from Boehringer Ingelheim. A.P.A. has received relevant research support through grants from the NIH (R01HL173866 and R01AG091005), the FDA (U01FD008704), the AHA, The Permanente Medical Group, Kaiser Permanente Northern California Community Health Programs, Garfield Memorial Fund, Abbott Laboratories, Abiomed, Amarin Pharma, Inc., Bayer Pharma AG, Boehringer Ingelheim, Cordio Medical, Edwards Lifesciences LLC, Esperion Therapeutics, Inc., Merck, and Novartis. Consulting for Bristol Meyer Squibb, Bayer Pharma AG, Corstasis, Merck, Novo Nordisk, Pharmacosmos A\/S, Pfizer, scPharma, SQ Innovation, Reprieve Cardiovascular, and VisCardia. N.G. reports honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Novartis, NovoNordisk, Roche Diagnostics, NP Medical and Echosens. L.M. has received a travel grant from Boehringer Ingelheim. All conflicts of interest have been declared outside the present work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}